Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Page 1
Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort.
Frantzi N, Nguyen XP, Herr C, Alter P, Söhler S, Soriano D, Watz H, Waschki B, Trinkmann F, Eichenlaub M, Trudzinski FC, Michels-Zetsche JD, Omlor A, Seiler F, Moneke I, Biertz F, Rohde G, Stolz D, Welte T, Kauczor HU, Kahnert K, Jörres RA, Vogelmeier CF, Bals R, Fähndrich S; German COSYCONET Cohort. Frantzi N, et al. Respir Res. 2024 May 15;25(1):207. doi: 10.1186/s12931-024-02822-1. Respir Res. 2024. PMID: 38750572 Free PMC article.
Other Study ID (BMBF grant): 01GI0881, registered 18 November 2010, study start 2010-11, primary completion 2013-12, study completion 2023-09. https://clinicaltrials.gov/study/NCT01245933?cond=COPD&term=COSYCONET&rank=3....
Other Study ID (BMBF grant): 01GI0881, registered 18 November 2010, study start 2010-11, primary completion 2013-12, study completion 2023-0 …
Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD): rationale, aims and design of a nationwide prospective registry.
Behr J, Bonella F, Günther A, Koschel D, Prasse A, Pittrow D, Klotsche J, Kreuter M; INSIGHTS-ILD Study Group. Behr J, et al. BMC Pulm Med. 2023 Feb 11;23(1):64. doi: 10.1186/s12890-023-02333-7. BMC Pulm Med. 2023. PMID: 36774483 Free PMC article.
METHODS/DESIGN: INSIGHTS-ILD is a prospective observational longitudinal registry designed to describe characteristics, management and course of newly diagnosed (incident) and prevalent patients with fILD on the long term. The registry uses a non-probability sampling appro …
METHODS/DESIGN: INSIGHTS-ILD is a prospective observational longitudinal registry designed to describe characteristics, management and cours …
Neuropsychiatric phenotype of post COVID-19 syndrome in non-hospitalized patients.
Lier J, Stoll K, Obrig H, Baum P, Deterding L, Bernsdorff N, Hermsdorf F, Kunis I, Bräsecke A, Herzig S, Schroeter ML, Thöne-Otto A, Riedel-Heller SG, Laufs U, Wirtz H, Classen J, Saur D. Lier J, et al. Among authors: wirtz h. Front Neurol. 2022 Sep 27;13:988359. doi: 10.3389/fneur.2022.988359. eCollection 2022. Front Neurol. 2022. PMID: 36237627 Free PMC article.
The strong association of psychiatric and psychosomatic symptoms with the PCFS warrants a systematic evaluation of psychosocial side effects of the pandemic itself and psychiatric comorbidities on the long-term outcome of patients with SARS-CoV-2 infection....
The strong association of psychiatric and psychosomatic symptoms with the PCFS warrants a systematic evaluation of psychosocial side effects …
Disease Progression and Age as Factors Underlying Multimorbidity in Patients with COPD: Results from COSYCONET.
Alter P, Kahnert K, Trudzinski FC, Bals R, Watz H, Speicher T, Söhler S, Andreas S, Welte T, Rabe KF, Wouters EFM, Sassmann-Schweda A, Wirtz H, Ficker JH, Vogelmeier CF, Jörres RA. Alter P, et al. Among authors: wirtz h. Int J Chron Obstruct Pulmon Dis. 2022 Jul 29;17:1703-1713. doi: 10.2147/COPD.S364812. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 35936574 Free PMC article.
We estimated to what extent increases in the prevalence of multimorbidity over time are attributable to COPD progression compared to increasing patient age. METHODS: Patients with COPD from the long-term COSYCONET (COPD and Systemic Consequences - Comorbidities Network) co …
We estimated to what extent increases in the prevalence of multimorbidity over time are attributable to COPD progression compared to increas …
Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.
Kaemmerer AS, Gorenflo M, Huscher D, Pittrow D, Ewert P, Pausch C, Delcroix M, Ghofrani HA, Hoeper MM, Kozlik-Feldmann R, Skride A, Stähler G, Vizza CD, Jureviciene E, Jancauskaite D, Gumbiene L, Ewert R, Dähnert I, Held M, Halank M, Skowasch D, Klose H, Wilkens H, Milger K, Jux C, Koestenberger M, Scelsi L, Brunnemer E, Hofbeck M, Ulrich S, Vonk Noordegraaf A, Lange TJ, Bruch L, Konstantinides S, Claussen M, Löffler-Ragg J, Wirtz H, Apitz C, Neidenbach R, Freilinger S, Nemes A, Opitz C, Grünig E, Rosenkranz S. Kaemmerer AS, et al. Among authors: wirtz h. Cardiovasc Diagn Ther. 2021 Dec;11(6):1255-1268. doi: 10.21037/cdt-21-351. Cardiovasc Diagn Ther. 2021. PMID: 35070795 Free PMC article.
Because clinical-trial data on PAH associated with CHD (PAH-CHD) remain limited, registry data on the long-term course are essential. This analysis aimed to update information from the COMPERA-CHD registry on management strategies based on real-world data. ...
Because clinical-trial data on PAH associated with CHD (PAH-CHD) remain limited, registry data on the long-term course are essential. …
[Molecule pathology in the treatment of lung cancer-Interdisciplinary view of the importance in thoracic surgery].
Krämer S, Wirtz H. Krämer S, et al. Among authors: wirtz h. Chirurg. 2022 May;93(5):485-489. doi: 10.1007/s00104-021-01544-0. Epub 2021 Dec 14. Chirurg. 2022. PMID: 34905081 Free PMC article. Review. German.
Interdisciplinary concepts can individually guarantee the long-term survival of the patient....
Interdisciplinary concepts can individually guarantee the long-term survival of the patient....
A randomized controlled trial of liposomal cyclosporine A for inhalation in the prevention of bronchiolitis obliterans syndrome following lung transplantation.
Neurohr C, Kneidinger N, Ghiani A, Monforte V, Knoop C, Jaksch P, Parmar J, Ussetti P, Sole A, Müller-Quernheim J, Kessler R, Wirtz H, Boerner G, Denk O, Prante Fernandes S, Behr J. Neurohr C, et al. Among authors: wirtz h. Am J Transplant. 2022 Jan;22(1):222-229. doi: 10.1111/ajt.16858. Epub 2021 Oct 18. Am J Transplant. 2022. PMID: 34587371 Free article. Clinical Trial.
Long-term survival after lung transplantation is limited by chronic allograft dysfunction. ...
Long-term survival after lung transplantation is limited by chronic allograft dysfunction. ...
Coil embolisation for massive haemoptysis in cystic fibrosis.
Dohna M, Renz DM, Stehling F, Dohna-Schwake C, Sutharsan S, Neurohr C, Wirtz H, Eickmeier O, Grosse-Onnebrink J, Sauerbrey A, Soditt V, Poplawska K, Wacker F, Montag MJ. Dohna M, et al. Among authors: wirtz h. BMJ Open Respir Res. 2021 Aug;8(1):e000985. doi: 10.1136/bmjresp-2021-000985. BMJ Open Respir Res. 2021. PMID: 34385150 Free PMC article.
INTRODUCTION: Massive haemoptysis is a life-threatening event in advanced cystic fibrosis (CF) lung disease with bronchial artery embolisation (BAE) as standard of care treatment. The aim of our study was to scrutinise short-term and long-term outcomes of patients w …
INTRODUCTION: Massive haemoptysis is a life-threatening event in advanced cystic fibrosis (CF) lung disease with bronchial artery embolisati …
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman A, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, Barnes J, Linde PG, de Oliveira Pena J, Badesch DB; PULSAR Trial Investigators. Humbert M, et al. N Engl J Med. 2021 Apr 1;384(13):1204-1215. doi: 10.1056/NEJMoa2024277. N Engl J Med. 2021. PMID: 33789009 Clinical Trial.
BACKGROUND: Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is associated with both hereditary and idiopathic subtypes. ...
BACKGROUND: Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term …
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Ghofrani HA, Gomez Sanchez MA, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano Subias P, Mielniczuk LM, Lange TJ, Vachiéry JL, Wirtz H, Helmersen DS, Tsangaris I, Barberá JA, Pepke-Zaba J, Boonstra A, Rosenkranz S, Ulrich S, Steringer-Mascherbauer R, Delcroix M, Jansa P, Šimková I, Giannakoulas G, Klotsche J, Williams E, Meier C, Hoeper MM; NEW COLLABORATORS LIST. Ghofrani HA, et al. Among authors: wirtz h. Respir Med. 2021 Mar;178:106220. doi: 10.1016/j.rmed.2020.106220. Epub 2020 Nov 12. Respir Med. 2021. PMID: 33540340 Free article.
The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort st …
The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety o …
37 results